BCRX

BioCryst has executed a genuine inflection. Revenue compounded from $157M (FY2021) to $875M (FY2025), and FY2025 marks the first GAAP-profitable year in the company's history: net income of $264M, a 39.0% operating margin, 30.2% net margin, and $347M of operating cash flow (+767.8%). Management used that cash to extinguish long-term debt (now $0.00, down 100%), leaving a single-product cash engine — ORLADEYO, the oral once-daily HAE prophylaxis — generating real free cash. At $9.55 the stock is priced at 7.9x trailing EPS of $1.21 and 2.7x sales, undemanding multiples for a business throwing off this much cash with no debt. The recent -3.92% day and the price level suggest the market is not paying up for the turnaround.

The quality of the call hinges on durability, and the filing is candid that it is not assured. Management writes it 'achieved net income on a U.S. GAAP basis... for the first time on an annual basis' but has 'not yet achieved sustained profitability,' and flags Q1 seasonality as payors force prescription reauthorizations that temporarily shift patients to free product. The +94.1% revenue jump and +13,508.9% leap in operating income are not a run-rate; with management guiding ORLADEYO to a ~$1B global peak, the FY2025 base of $875M implies the core franchise is already near its ceiling and growth must decelerate sharply. Future upside therefore depends on the pipeline, not the base business.